Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Short position
Mesoblast (ASX:MSB) has 7.57% of its shares on issue reported as short positions as of 5 Oct 2026, or about 98,260,040 shares. Over the past 30 days that figure has risen 0.64 percentage points, and over 90 days it has fallen 0.78 percentage points. Its highest recorded short interest was 11.00% in October 2015. MSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Mesoblast (MSB) short interest history
MSB Short Interest History
- 30-day change
- +0.64pp
- 90-day change
- -0.78pp
- 1-year change
- +0.93pp
- All-time high
- 11.00% (October 2015)
- All-time low
- 0.00% (August 2010)
Is MSB heavily shorted?
MSB's short interest of 7.57% is elevated relative to the ASX average, ranking #33 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has MSB's short interest changed recently?
Over the past 30 days Mesoblast's short interest has risen 0.64 percentage points, and over 90 days it has fallen 0.78 percentage points. The current level is 7.57% of shares on issue.
What is the highest MSB's short interest has been?
Since 2010, Mesoblast's short interest peaked at 11.00% in October 2015 and bottomed at 0.00% in August 2010.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2010. See our methodology.